Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 9 January 2026 - 12 January 2026

UnitedHealth stock slides after Senate Medicare report; UNH investors eye Jan. 27 outlook

UnitedHealth stock slides after Senate Medicare report; UNH investors eye Jan. 27 outlook

NEW YORK, Jan 12, 2026, 13:48 EST — Regular session Shares of UnitedHealth Group Incorporated dropped Monday following a U.S. Senate report accusing the insurer of using aggressive tactics to boost Medicare Advantage payments. The stock dipped 1.5% to $338.89 in early afternoon trading. (Reuters) The report arrives amid heightened scrutiny of managed-care stocks, with investors digesting the potential for stricter oversight and more payment changes in Medicare Advantage—a key revenue driver for the sector. UnitedHealth plans to reveal its 2026 outlook later this month, and any signals that audits or repayments could increase usually rattle investor confidence early on.
12 January 2026
····
Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play

New York, January 12, 2026, 05:24 EST — Premarket Mereo BioPharma Group plc shares held steady near $0.49 in U.S. premarket trading Monday, following a strong 28.6% jump to $0.4944 at Friday’s close. (The Wall Street Journal) Timing is key here. The J.P. Morgan Healthcare Conference is set for Jan. 12-15 in San Francisco, a week known for sharp moves in small biotech stocks on any news of partnerships, cost reductions, or strategic shifts. Last week, Mereo announced that CEO Denise Scots-Knight will present on Jan. 14. (JPMorgan Chase) Mereo has been struggling to bounce back since late December, when
12 January 2026
····
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Copenhagen, January 11, 2026, 23:22 CET — Market closed Novo Nordisk (NOVOb.CO) shares climbed 3% to 381.45 Danish crowns on Friday after Amazon Pharmacy announced it will offer the drugmaker’s Wegovy weight-loss pill through insurance coverage as well as a cash-pay option. The U.S.-listed ADRs (NVO) closed 2.6% higher at $58.81. (Reuters) Novo’s new distribution channel is crucial as the company seeks to steady sentiment following a rough 2025. In July, the stock plunged almost 30% in one day after it lowered its 2025 sales forecast. Since then, investors have been quick to sell on any sign of weakening U.S.
11 January 2026
······
Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears

Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears

New York, January 11, 2026, 15:30 EST — Market closed. Abbott Laboratories starts the week with its proposed acquisition of Exact Sciences in the spotlight, following Exact Sciences’ announcement of a shareholder vote scheduled for Feb. 20. Timing is crucial here since Abbott’s quarterly results come out on Jan. 22. That report could reset expectations for 2026 and clarify just how much management plans to spend—and absorb—in pursuit of growth. Wall Street is tugging in opposite directions. Bernstein’s Lee Hambright nudged his price target up to $154 from $150. On the flip side, Goldman Sachs trimmed its target to $152
11 January 2026
······
AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

New York, January 11, 2026, 11:10 EST — Market closed AbbVie Inc. (ABBV.N) closed Friday down 1.8% at $220.08. As U.S. markets remain closed over the weekend, chatter about a potential deal lingers heading into Monday. The J.P. Morgan Healthcare Conference week draws attention now, serving as a hotspot for new guidance, pipeline updates, and those crucial side-room talks that often spark M&A activity. For major drugmakers, it’s also the moment investors demand a clear answer: should they buy growth or build it themselves? Deal advisers told Reuters they expect a surge in large healthcare M&A deals in 2026 as
11 January 2026
····
Smith & Nephew stock: CEO’s JPMorgan talk is the next test after Friday’s dip

Smith & Nephew stock: CEO’s JPMorgan talk is the next test after Friday’s dip

London, Jan 11, 2026, 09:07 GMT — Market closed. Smith & Nephew (SN.L) heads into the new week with a near-term catalyst on the calendar: CEO Deepak Nath is set to present at the JPMorgan Healthcare Conference on Monday. The stock closed on Friday at 1,258 pence, down 0.9%. (Smith & Nephew) That matters because the broader tape was upbeat into the weekend. London’s FTSE 100 closed at a record high on Friday, lifted by a jump in Glencore and a U.S. jobs report that kept rate-cut bets alive. (Reuters) Healthcare did not lead the move. Market summaries of Friday’s
11 January 2026
····
Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

Wave Life Sciences stock drops 7% into JPM Healthcare Conference week — what to know next

New York, January 10, 2026, 21:25 EST — Market closed Shares of Wave Life Sciences Ltd dropped 6.7% on Friday, ending the day at $13.84. The stock swung between a high of $15.09 and a low of $13.76 during the session. As the J.P. Morgan Healthcare Conference week kicks off, investors are eyeing Wave’s stock for any new insights on its pipeline and upcoming milestones. CEO Paul Bolno is set to speak on Tuesday. (GlobeNewswire) The San Francisco event is a key date for healthcare investors and bankers, sparking deal chatter and fresh moves in biotech. This week, a Reuters
11 January 2026
·····
Amgen stock slides into weekend as JPMorgan healthcare conference looms

Amgen stock slides into weekend as JPMorgan healthcare conference looms

NEW YORK, Jan 10, 2026, 17:43 EST — Market closed. Shares of Amgen Inc. closed down on Friday, marking a second consecutive day of losses as investors prepared for a new batch of healthcare conference updates. The timing is key as deal discussions pick up again with executives and bankers gathering in San Francisco for the J.P. Morgan Healthcare Conference, a major early-year event for the sector. Jeremy Meilman, JPMorgan’s global co-head of healthcare investment banking, noted that firms are “dusting off the playbook on the art of the possible.” (Reuters) Amgen finds itself in a familiar yet tricky position:
10 January 2026
·····
Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage

Abbott Laboratories stock drifts into earnings after Canada widens Libre 3 Plus coverage

New York, January 10, 2026, 16:02 EST — Market closed Abbott Laboratories (ABT) said its FreeStyle Libre 3 Plus glucose sensor is now publicly funded across every province in Canada. The stock ended down 0.2% at $125.92 on Friday. (Nasdaq) The update lands with investors turning back to Abbott’s diabetes-device franchise heading into fourth-quarter results later this month. Abbott said it will report before the U.S. market opens on Jan. 22 and host a webcast that morning. (Abbott MediaRoom) Analysts have started to revisit targets on large-cap healthcare names after a shaky 2025 run. Bernstein analyst Lee Hambright raised Abbott’s
10 January 2026
·····
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

NEW YORK, Jan 10, 2026, 13:31 EST — Market closed U.S. healthcare stocks ended the week weaker, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.5% to $157.31 on Friday. This ETF, often seen as a benchmark for major U.S. healthcare companies, has shown volatility as investors brace for a packed schedule of sector developments. The industry’s annual dealmaking and investor tour is about to ramp up, and healthcare’s stakes are high. Traders are debating if this year will see a surge in biotech and medtech acquisitions, and whether major drugmakers move from discussion to actual deals. The
10 January 2026
······
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon.com (AMZN.O) shares rose 0.4% in after-hours trading on Friday after Amazon Pharmacy said it has begun offering Novo Nordisk’s (NOVOb.CO) Wegovy weight-loss pill via insurance plans as well as a cash-pay option. Customers who qualify and have commercial insurance could pay $25 for a one-month supply, while cash-pay begins at $149; the U.S. FDA approved the pill in December, Amazon said. AMZN last traded at $247.33, after ranging from $242.31 to $247.71 during the session. Novo has said the pill will also be available through CVS and Costco and through telehealth providers including Ro, LifeMD, WeightWatchers and GoodRx. (Reuters)
9 January 2026
······
TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next

TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next

New York, January 9, 2026, 15:59 (EST) — Regular session TG Therapeutics (TGTX.O) shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session. The move comes with the J.P. Morgan Healthcare Conference set to kick off on Monday in San Francisco, a meeting that often pulls in fresh corporate updates and deal chatter in one tight week. The bank’s agenda shows the event runs
9 January 2026
·····
1 … 3 4 5 6 7 … 13

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:31 AM EST Dollar Dips as Stocks Rally and US Data Influences Fed Rate Expectations February 7, 2026, 12:18 AM EST. The **dollar index** fell 0.17%, pressured by a rebound in equity markets reducing demand for the safe-haven currency. Weaker-than-expected U.S. labor market data raised the odds of a Fed rate cut to 18% for March, though consumer sentiment improved to a six-month high, limiting losses. Hawkish comments from Atlanta Fed's Raphael Bostic emphasized maintaining restrictive monetary policy. The dollar faces medium-term weakness amid expectations for rate cuts
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop